Skip to main content

Table 1 Patient and treatment characteristics

From: The efficacy and safety of apatinib treatment for patients with advanced or recurrent biliary tract cancer: a retrospective study

Characteristic Total(n = 28)
n (%)
Monotherapy(n = 12)
n (%)
Combination therapy(n = 16)
n (%)
P
Age (years, median) 54 (36–79) 52 (36–79) 57 (43–64)  
Sex
 Female 12 (42.9) 5 (41.7) 7 (43.8) 0.912
 Male 16 (57.1) 7 (58.3) 9 (56.2)  
ECOG
 0–1 22 (78.6) 10 (83.3) 12 (75.0) 0.595
 2 6 (21.4) 2 (16.7) 4 (25.0)  
Primary tumor site
 GBC 9 (32.1) 3 (25.0) 6 (37.5) 0.483
 CCA 19 (67.9) 9 (75.0) 10 (62.5)  
Metastatic site
 Intra-abdominal lymph node 16 (57.1) 6 (50.0) 10 (62.5)  
 Liver 14 (50.0) 2 (16.7) 12 (75.0) 0.086
 Peritoneum 8 (28.6) 3 (25.0) 5 (31.3)  
 Lung 8 (28.6) 6 (50.0) 2 (12.5)  
 Others 16 (57.1) 7 (58.3) 9 (56.3)  
Number of metastatic sites
 1–2 13 (46.4) 5 (41.7) 8 (50.0) 0.662
  ≥ 3
 Treatment line
15 (53.6) 7 (58.3) 8 (50.0)  
 2 11 (39.3) 5 (41.7) 6 (37.5) 0.823
 3–4 17 (60.7) 7 (58.3) 10 (62.5)  
  1. ECOG Eastern Cooperative Oncology Group performance status, GBC gallbladder cancer, CCA Cholangiocarcinoma